Rubicon Analysis IPO: The preliminary public providing (IPO) of Rubicon Analysis Restricted stepped into its closing day of public bidding right now, October 13. The problem has seen an total subscription of 13.42 occasions thus far, as per provisional alternate information. The corporate goals to boost Rs 1377.50 crore from the general public providing of two.84 crore fairness shares.
The premise of allotment for the IPO shares is anticipated to be finalised on October 14, 2025.
Rubicon Analysis IPO subscription standing:
By midday, buyers have bid for 22.08 crore shares in opposition to the entire shares on provide, together with main calls for from non-institutional and retail investor classes.
Add Zee Enterprise as a Most well-liked Supply
Primarily, Certified Institutional Consumers (QIBs), Non-Institutional Buyers (NIIs) and Retail Particular person Buyers (RIIs) have booked 2.27 occasions, 34.14 occasions, and 15.84 occasions thus far in opposition to their allotted parts, respectively.
When it comes to shares, the QIB, NII and RII classes have seen subscription of round 2.03 crore, 15.28 crore and 4.72 crore shares in opposition to their reserved portion, respectively.
Learn Extra: Canara Robeco IPO closing day: Do you have to subscribe? Here is what Anil Singhvi suggests
Rubicon Analysis IPO particulars:
The Rubicon Analysis IPO is a book-building subject of Rs 1,377.50 crore, together with a recent subject of 1.03 crore fairness shares of Rs 500 crore and a suggestion on the market (OFS) of 1.80 crore fairness shares of Rs 877.50 crore.
The corporate has reserved roughly 36,082 fairness shares (primarily based on the higher cap) for its eligible workers.
The corporate plans to utilise the IPO proceeds for debt reimbursement, funding inorganic progress and for common company functions.
Worth band: Rs 461 to Rs 485 per fairness share
Face worth: Re 1 every
Subscription date: October 9 to October 13, 2025
Lot measurement: 30 shares
Minimal funding: Rs 14,550 primarily based on the higher finish of the value band
Allotment date: October 14, 2025
Itemizing date: October 16 on BSE and NSE
Rubicon Analysis firm profile:
Rubicon Analysis Restricted is a pharmaceutical formulations firm with a powerful presence in regulated markets, notably america.
The corporate has a portfolio of 66 commercialised merchandise and 72 lively ANDAs and NDAs permitted by the US FDA.
Financially, it reported a web revenue of Rs. 43.30 crore on a complete revenue of Rs. 356.95 crore in Q1 FY26, which ended on June 30, 2025, from a web revenue of Rs. 25.57 crore on a complete revenue of Rs. 321.90 crore for the earlier interval.
